Dexfadrostat Phosphate (DP13) & DP14 Diagnostic

About Damian Pharma

Damian Pharma is a clinical-stage biotech targeting a high-unmet need in endocrinology with a first-in-class therapy for Primary Aldosteronism (PA). The company's lead asset, dexfadrostat phosphate (DP13), has completed Phase I and a Phase II study, positioning it as a potential targeted medical alternative to surgery. Backed by a small team of seasoned pharmaceutical executives and scientists, Damian is leveraging a clear biological pathway to develop a precision medicine solution for a rare but serious endocrine disorder.

Therapeutic Areas